Evidence map›Paper›PMID 34538699›Full record

ArticleVaccine2021

The use of face masks during vaccine roll-out in New YorkCity and impact on epidemic control.

C Raina MacIntyre, Valentina Costantino, Arjun Chanmugam

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

C Raina MacIntyreThe Biosecurity Program, The Kirby Institute, University of New South Wales, Australia; College of Health Solutions, Arizona State University, AZ, USA; Watts College of Public Affairs and Community Solutions, Arizona State University, AZ, USA.
Valentina CostantinoThe Biosecurity Program, The Kirby Institute, University of New South Wales, Australia. Electronic address: vale.cost@protonmail.com.
Arjun ChanmugamJohns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MND, USA.
UNSW Sydney · AUJohns Hopkins University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Face masks were mandated in New York during the first wave in 2020, and in 2021 the first vaccine programs have commenced. We aimed to examine the impact of face mask and other NPIs use with a gradual roll out of vaccines in NYC on the epidemic trajectory. A SEIR mathematical model of SARS-CoV-2 transmission was developed for New York City (NYC), which accounted for decreased mobility for lockdown, testing and tracing. Varied mask's usage and efficacy were tested, along with a gradual increase in vaccine uptake over five months. The model has been calibrated using notification data in NYC from March first to June 29. Masks and other NPIs result in immediate impact on the epidemic, while vaccination has a delayed impact, especially when implemented over a long period of time. A pre-emptive, early mandate for masks is more effective than late mask use, but even late mask mandates will reduce cases and deaths by over 20%. The epidemic curve is suppressed by at least 50% of people wearing a mask from the start of the outbreak but surges when mask wearing drops to 30% or less. With a slow roll out of vaccines over five months at uptake levels of 20-70%, NPIs use will still be needed and has a greater impact on epidemic control. When vaccine roll out is slow or partial in cities experiencing local transmission of COVID-19, masks and other NPIs will be necessary to mitigate transmission until vaccine coverage is high and complete. Vaccine alone cannot rapidly control an epidemic because of the time lag to two-dose immunity. Even after high coverage, the ongoing need for NPIs is unknown and will depend on long-term duration of vaccine efficacy, the use of boosters and optimized dosage scheduling and variants of concern.

Indexed as

COVID-19EpidemicsVaccinesCommunicable Disease ControlHumansMasksNew York CitySARS-CoV-2Vaccines

Identifiers

PMID34538699
PMCPMC8443976
OpenAlexW3200122057

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.